VANCOUVER, March 6 /CNW/ - Zecotek Medical Systems Inc. (TSX-V: ZMS;
Frankfurt: W1I.F) today announced that it has filed three patent applications
with the U.S. Patent Office related to its product line of new-generation
solid-state photon counters, known as MAPD (Micro-pixel Avalanche Photo
"The filing of patents for our new-generation solid-state photon counters
is a very important step in our strategy of protecting our intellectual
property and further extends Zecotek's leadership in this very important area
of medical imaging technology," said Dr. A. F. Zerrouk, Chairman, President
and CEO of Zecotek.
Zecotek also announced today that Prof. Zair Sadygov, the inventor of the
MAPD and the founder of Dubna-Detectors Ltd., a research and development
company working within the Institute of Nuclear Research in Dubna, Russia, has
been appointed Chief Scientist in Zecotek's medical imaging division. Prof.
Sadygov will lead the development and production of Zecotek's product line of
solid-state photon counters including the latest generation device, known as
the Micro-Channel MAPD (MC-MAPD). The variety in operational parameters of
these solid-sate photon counters will offer the imaging industry at large a
choice of detection design considerations. This will be particularly important
for PET (Positron Emission Tomography) scanners. The appointment expands
Zecotek's existing relationship with Dubna-Detectors Ltd. and its exclusive
partnership whereby Zecotek owns all rights, title and interest in current and
future generations of photo-detector devices researched and developed by Prof.
Sadygov and his team of scientists.
"We are extremely fortunate to have Prof. Sadygov join our medical
imaging team as he is recognized as the world leader in the development of
solid-state photon counters," continued Dr. A. F. Zerrouk. "The combined
expertise of Zecotek and Prof. Sadygov and his team is highly synergistic as
Zecotek's scintillation materials combined with the new-generation solid-state
photon counters will create higher resolution diagnostic machines for the
medical imaging market. Prof. Sadygov is an integral member of our medical
Zecotek's solid-state photon counters (MAPD and MC-MAPD) have been
designed to offer significant cost and performance advantages over the current
vacuum tube based Photo Multiplier Tubes (PMT). PMT based photo-detection
devices form a major cost component in the US$1 billion market for PET and
PET-CT scanners, representing approximately one-third of the cost of each
unit. Existing PMT's are also key components of medical inspection devices
used in blood analysis and DNA sequencing. Additional non-medical applications
include: gamma ray detectors for homeland security, environmental monitoring,
industrial control systems, robotics, biomedical testing, navigation and
guidance systems, laser radars and high energy physics.
Production of Zecotek's photon counters is expected to begin in Q2 of
this calendar year with one of Singapore's highly competitive microelectronics
wafer fabricators. Requests for immediate testing have been received from
Zecotek Medical Systems (TSX-V: ZMS; Frankfurt- W1I.F) is a bio-photonics
technology company developing high-performance crystals, photo detectors,
medical lasers, optical imaging and 3D display technologies for commercial
applications in the medical diagnostics and high-tech industry. Founded in
2003, the company has three distinct operating divisions: medical imaging,
medical lasers and 3D display and labs located in Canada, Singapore and
Russia. Zecotek commercializes its novel, patented and patent-pending
bio-photonic technologies directly and through strategic alliances and joint
ventures with multinational OEMs, distributors and other industry leaders.
This press release may contain forward-looking statements that are based
on management's expectations, estimates, projections and assumptions. These
statements are not guarantees of future performance and involve certain risks
and uncertainties, which are difficult to predict. Therefore, actual future
results and trends may differ materially from what may have been stated.
For additional information on Zecotek Medical Systems and our
technologies please see our website at www.zecotekmed.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release. If you would like to receive news from Zecotek in the future,
please email firstname.lastname@example.org and mention "ZMS News" in the subject
heading or visit the corporate website at www.zecotekmed.com.
For further information:
For further information: MICHAEL MINDER, CFO; VP Corporate Development,
T: (604) 827-5203, E: email@example.com